Hospitality Properties Trust (Nasdaq: HPT) today announced a regular quarterly common share distribution of $0.51 per common share ($2.04 per share per year). This distribution will be paid...
Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Hyperion Therapeutics, Inc. Juan E. Monteverde, a...
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Hyperion Therapeutics, Inc. (NASDAQ: HPTX) (“Hyperion” or “the Company”) in connection...
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Hyperion Therapeutics, Inc. ("Hyperion” or "the Company...
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Hyperion Therapeutics, Inc. (NASDAQ: HPTX) (“Hyperion” or “the Company”) in connection...
Law Offices of Marc S. Henzel Announces Securities Class Action Periods PR Newswire MERION, Pa., April 7, 2015 MERION, Pa., April 7, 2015 /PRNewswire/ -- The Law Offices of Marc S. Henzel...
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by...
HYPERION THERAPEUTICS INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Hyperion Therapeutics, Inc. Over the Proposed Sale of the Company to Horizon Pharma, Plc...
WeissLaw LLP: The Hyperion Therapeutics, Inc. Acquisition by Horizon Pharma Plc Is the Subject of a Legal Investigation PR Newswire NEW YORK, April 3, 2015 NEW YORK, April 3, 2015 /PRNewswire/...
HPTX SHAREHOLDER ALERT: The Law Offices of Vincent Wong Launches an Investigation of the Board of Directors of Hyperion Therapeutics, Inc. Concerning the Sale of the Company to Horizon Pharma...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관